Shots:

• Lundbeck acquires Abide- in all-stock transaction for $400M. Abide to receive $250M upfront and $150M development & commercialization milestones with its expected closure in Q2’19
• The focus of the acquisition is to strengthen Lundbeck’s CNS portfolio with the addition of Abide’s candidate (ABX-1431) and a chemo-proteomic platform for developing serine hydrolase inhibitors (SHs) to treat multiple CNS disorders
• Abide’s ABX-1431 is a selective inhibitor of serine hydrolase monoacylglycerol lipase (MGLL)- increasing endocannabinoid signaling to restore homeostatic balance in CNS and is evaluated in P-IIa & P-I for Tourette syndrome & neuropathic pain respectively

Ref: Lundbeck | Image: Lundbeck